NASDAQ:DXCM - DexCom Stock Price, News & Analysis

$173.55
-0.82 (-0.47 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$172.4450
Now: $173.55
$176.59
50-Day Range
$142.68
MA: $153.80
$175.20
52-Week Range
$105.05
Now: $173.55
$176.59
Volume1.13 million shs
Average Volume992,471 shs
Market Capitalization$15.83 billion
P/E Ratio234.04
Dividend YieldN/A
Beta0.8
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.03 billion
Cash Flow$0.6271 per share
Book Value$7.55 per share

Profitability

Net Income$-127,100,000.00

Miscellaneous

Employees2,800
Market Cap$15.83 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.


DexCom (NASDAQ:DXCM) Frequently Asked Questions

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Wednesday, July, 31st. The medical device company reported $0.08 EPS for the quarter, beating the Zacks' consensus estimate of $0.01 by $0.07. The medical device company earned $336.40 million during the quarter, compared to the consensus estimate of $304.40 million. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The business's revenue for the quarter was up 38.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.10) earnings per share. View DexCom's Earnings History.

When is DexCom's next earnings date?

DexCom is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for DexCom.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.325-1.375 billion, compared to the consensus revenue estimate of $1.29 billion.

What price target have analysts set for DXCM?

16 brokerages have issued 12 month price objectives for DexCom's shares. Their forecasts range from $125.00 to $190.00. On average, they expect DexCom's stock price to reach $167.00 in the next twelve months. This suggests that the stock has a possible downside of 3.8%. View Analyst Price Targets for DexCom.

What is the consensus analysts' recommendation for DexCom?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

What are Wall Street analysts saying about DexCom stock?

Here are some recent quotes from research analysts about DexCom stock:
  • 1. According to Zacks Investment Research, "Shares of the company have outperformed the industry in a year's time. Strong contributions from the Sensor and Transmitter segments have been key catalysts. Further, solid guidance instills optimism in the stock. The glucose monitoring market presents significant commercial opportunity for DexCom. Opportunities in alternative markets such as the non-intensive diabetes management space, hospital, gestational, pre-diabetes and obesity are likely to provide DexCom a competitive edge in the MedTech space. Meanwhile, cutthroat competition in the market for blood & glucose monitoring devices remains a headwind. With respect to quarterly results, DexCom exited the second quarter on a strong note, wherein both the top and bottom line beat the Zacks Consensus Estimate." (8/12/2019)
  • 2. Northland Securities analysts commented, "We present here a comparative assessment of 2.0 data readouts. Our global view is….we love Dexcom, but believe the story is going to be pressured on all fronts….top-line growth, margins, and market share. If this data is representative of the FDA submission (or part thereof), there is no doubt that Libre 2.0 will get an i" designation." (6/6/2019)

Has DexCom been receiving favorable news coverage?

News coverage about DXCM stock has trended positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DexCom earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for DexCom.

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Tandem Diabetes Care (TNDM), salesforce.com (CRM), Paypal (PYPL), Home Depot (HD), Micron Technology (MU), ServiceNow (NOW) and GW Pharmaceuticals PLC- (GWPH).

Who are DexCom's key executives?

DexCom's management team includes the folowing people:
  • Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
  • Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
  • Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
  • Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.00%), Price T Rowe Associates Inc. MD (5.98%), Baillie Gifford & Co. (5.30%), Brown Advisory Inc. (2.94%), Jennison Associates LLC (1.53%) and Jennison Associates LLC (1.53%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

Which major investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Renaissance Technologies LLC, William Blair Investment Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Vanguard Group Inc., AQR Capital Management LLC and First Trust Advisors LP. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

Which major investors are buying DexCom stock?

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Jennison Associates LLC, Jennison Associates LLC, Orbimed Advisors LLC, C WorldWide Group Holding A S, Bamco Inc. NY and Point72 Asset Management L.P.. View Insider Buying and Selling for DexCom.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $173.55.

How big of a company is DexCom?

DexCom has a market capitalization of $15.83 billion and generates $1.03 billion in revenue each year. The medical device company earns $-127,100,000.00 in net income (profit) each year or $0.30 on an earnings per share basis. DexCom employs 2,800 workers across the globe.View Additional Information About DexCom.

What is DexCom's official website?

The official website for DexCom is http://www.dexcom.com/.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]


MarketBeat Community Rating for DexCom (NASDAQ DXCM)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  755 (Vote Outperform)
Underperform Votes:  421 (Vote Underperform)
Total Votes:  1,176
MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel